Rallybio Corp
Company Profile
Business description
Rallybio Corp is a clinical-stage biotechnology company engaged in the development of therapeutic candidates for severe and rare diseases. It focuses on the treatment of conditions related to complement dysregulation and hematologic disorders. The company's flagship program, RLYB116, is a C5 inhibitor being evaluated for potential use in diseases associated with complement dysregulation, including immune platelet transfusion refractoriness and refractory antiphospholipid syndrome. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody candidate under investigation for the treatment of iron overload disorders.
Contact
234 Church Street
Suite 1020
New HavenCT06510
USAT: +1 203 859-3820
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
15
Stocks News & Analysis
stocks
Meta earnings: Strong end to 2025 as AI monetization begins to show
stocks
Why doesn’t the market like the earnings from this US tech giant?
stocks
Our Tesla fair value increases meaningfully
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,211.00 | 48.20 | -0.52% |
| CAC 40 | 8,071.36 | 4.68 | 0.06% |
| DAX 40 | 24,309.46 | 513.33 | -2.07% |
| Dow JONES (US) | 49,071.56 | 55.96 | 0.11% |
| FTSE 100 | 10,171.76 | 17.33 | 0.17% |
| HKSE | 27,613.19 | 354.90 | -1.27% |
| NASDAQ | 23,685.12 | 172.33 | -0.72% |
| Nikkei 225 | 53,153.70 | 221.90 | -0.42% |
| NZX 50 Index | 13,389.90 | 41.29 | 0.31% |
| S&P 500 | 6,969.01 | 9.02 | -0.13% |
| S&P/ASX 200 | 8,912.60 | 42.50 | -0.47% |
| SSE Composite Index | 4,113.95 | 44.04 | -1.06% |